April 30, 2013 — St. Jude Medical Inc. announced CE Mark approval and European launch of its Allure Quadra Cardiac Resynchronization Therapy Pacemaker (CRT-P). This CRT-P system offers more pacing options to deliver higher success rates, as evidenced by robust clinical data. Allure Quadra CRT-P brings the quadripolar lead technology to the pacemaker market. Quadripolar leads allow for increased implant efficiencies, which clinical data indicates can result in fewer surgical revisions. The Allure family of devices also offers heart failure (HF) diagnostics, including CorVue Impedance Monitoring, for improved patient management.
Approximately one in 10 patients who receive a bipolar CRT system has complications that could require additional surgery. St. Jude Medical’s quadripolar technology allows for additional pacing configurations that provide physicians with options not available on traditional bipolar systems. These additional options help manage common pacing complications without exposing the patient to additional surgeries for lead repositioning.
Additionally, the Allure CRT-P device improves HF management with timely access to vital diagnostic data including CorVue Impedance Monitoring for earlier insight into HF progression, and Direct Trend Reports for a simplified look at all device data. The Allure Quadra CRT-P integrates the best-in-class quadripolar technology with multiple pacing configurations and TailoredTherapy features designed to enable physicians to address the dynamic challenges of HF by optimizing the quadripolar system at implant and followup.
For more information: www.sjm.com
March 26, 2024 
